Skin Cancer: Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell CarcinomaResearch Question:
What are the good or bad effects of REGN2810 in patients with advanced cutaneous squamous
cell carcinoma? These effects could be good (for example, shrinking of tumors) or
bad (called side effects).
Basic Study Information
Purpose:Location: cancer center
REGN2810 is a type of drug called a monoclonal antibody. Antibodies are proteins
that are naturally found in your blood stream that fight infections. A monoclonal
antibody is a special kind of antibody that is created in a laboratory. It is a medication
that binds to specific proteins in the body that may be involved in your cancer.
This study is being done to test if REGN2810 can reduce the size of your tumor by
helping the immune system destroy the tumor. The study is also being done to test
the safety of REGN2810 in CSCC patients.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02760498?term=R2810-ONC-1540&rank=1
Study Reference #: IHAN-16064
Lead Researcher (Principal Investigator)
Lead Researcher: Sherrif Ibrahim
Study Contact InformationStudy Coordinator: Amy Jasek
Phone: (585) 273-1912
Additional Study Details
Learn More About These Conditions
More information about Carcinoma, Squamous Cell
Trial Not Found
The study you are looking for is not active at this time.
Return to Search